Literature DB >> 23553137

Suppression of the lipid peroxidation process in the CNS reduces neurological expression of experimentally induced autoimmune encephalomyelitis.

Srdjan Ljubisavljevic1, Ivana Stojanovic, Dusica Pavlovic, Maja Milojkovic, Dusan Sokolovic, Ivana Stevanovic, Aleksandar Petrovic.   

Abstract

OBJECTIVE: Here we report the influence of malondialdehyde (MDA) as a measure of the lipid peroxidation process (LP), on multiple sclerosis (MS) pathogenesis and its neurological signs, during the treatment with aminoguanidine (AG) - a selective inducible nitric oxide synthase inhibitor and N-Acetyl cysteine (NAC) - an oxidative scavenger, in the experimental autoimmune encephalomyelitis (EAE), an animal model for studying MS.
MATERIAL AND METHODS: Encephalomyelitis induction by the subcutaneous injection of myelin basic protein of bovine type, dissolved in phosphate buffered saline (PBS) emulsified in equal volume of the complete Freund's adjuvant (CFA), was described in detail in our earlier published papers. Each of animals was randomly assigned to seven groups - control (PBS), EAE, CFA, EAE + AG, AG, EAE + NAC and NAC group. In each animal, the development of neurological signs of EAE was scored, these results were published earlier. MDA was evaluated in the central nervous system (CNS) structure - cerebellums and spinal cords.
RESULTS: The obtained results show that the AG and NAC treatment significantly reduces the MDA level in both examined tissues (p < 0.05) ameliorating at the same time EAE clinical signs (p < 0.05).
CONCLUSIONS: Taking together our present and earlier findings we conclude that LP may provoke and promote MS, while blocking of this process results in amelioration of the clinical onset and disease activity. These results may be useful as a new insight into mechanisms and potential targets for therapeutic strategies in MS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23553137     DOI: 10.5114/fn.2013.34196

Source DB:  PubMed          Journal:  Folia Neuropathol        ISSN: 1509-572X            Impact factor:   2.038


  8 in total

Review 1.  Strain-Related Differences in the Immune Response: Relevance to Human Stroke.

Authors:  Kyra J Becker
Journal:  Transl Stroke Res       Date:  2016-02-10       Impact factor: 6.829

2.  The Use of Agmatine Provides the New Insight in an Experimental Model of Multiple Sclerosis.

Authors:  Milica Ninkovic; Ivana Stevanovic; Ivana Stojanovic; Srdjan Ljubisavljevic; Jelena Basic; Predrag Peric
Journal:  Neurochem Res       Date:  2015-07-04       Impact factor: 3.996

Review 3.  Oxidative Stress and Neurobiology of Demyelination.

Authors:  Srdjan Ljubisavljevic
Journal:  Mol Neurobiol       Date:  2014-12-11       Impact factor: 5.590

4.  One-time intrathecal triamcinolone acetonide application alters the redox potential in cerebrospinal fluid of progressive multiple sclerosis patients: a pilot study.

Authors:  Thomas Müller; Thomas Herrling; Sven Lütge; Lutz Lohse; Gabi Öhm; Katinka Jung
Journal:  Ther Adv Neurol Disord       Date:  2016-03-09       Impact factor: 6.570

5.  IFN-γ ameliorates autoimmune encephalomyelitis by limiting myelin lipid peroxidation.

Authors:  Rebecca A Sosa; Cathi Murphey; Rachel R Robinson; Thomas G Forsthuber
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-24       Impact factor: 11.205

Review 6.  Isoprostanes and neuroprostanes as biomarkers of oxidative stress in neurodegenerative diseases.

Authors:  Elżbieta Miller; Agnieszka Morel; Luciano Saso; Joanna Saluk
Journal:  Oxid Med Cell Longev       Date:  2014-04-29       Impact factor: 6.543

7.  Memantine Modulates Oxidative Stress in the Rat Brain following Experimental Autoimmune Encephalomyelitis.

Authors:  Beata Dąbrowska-Bouta; Lidia Strużyńska; Marta Sidoryk-Węgrzynowicz; Grzegorz Sulkowski
Journal:  Int J Mol Sci       Date:  2021-10-20       Impact factor: 5.923

8.  Piperine Improves Experimental Autoimmune Encephalomyelitis (EAE) in Lewis Rats Through its Neuroprotective, Anti-inflammatory, and Antioxidant Effects.

Authors:  Reza Nasrnezhad; Sohrab Halalkhor; Farzin Sadeghi; Fereshteh Pourabdolhossein
Journal:  Mol Neurobiol       Date:  2021-08-02       Impact factor: 5.590

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.